Is there an unrecognized epidemic of primary aldosteronism? (Pro)

被引:100
作者
Calhoun, David A. [1 ]
机构
[1] Univ Alabama Birmingham, Vasc Biol & Hypertens Program, Birmingham, AL USA
关键词
D O I
10.1161/HYPERTENSIONAHA.106.086116
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
A large body of evidence clearly establishes that PA is common, with a prevalence of ≈10% among general hypertensive populations and ≈20% among patients with resistant hypertension. Results of the recently published PAPY study indicate that, among patients with general hypertension, <5% will have an APA.11 Given this small percentage, it is not likely to be cost or risk efficient to fully evaluate all patients with hypertension for PA in order identify he few that will benefit for adrenalectomy. In contrast, because patients with resistant hypertension are by definition failing medical therapy, evaluation for PA seems appropriate to identify the 10% who likely have an APA and to guide dosing of mineralocorticoid receptor antagonists in the 10% who have idiopathic PA. © 2007 American Heart Association, Inc.
引用
收藏
页码:447 / 452
页数:6
相关论文
共 35 条
  • [1] Urinary tetra hyd roa idosterone as a screening method for primary aldosteronism: A Comparative Study
    Abdelhamid, S
    Blomer, R
    Hommel, G
    Haack, D
    Lewicka, S
    Fiegel, P
    Krurnme, B
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (07) : 522 - 530
  • [2] ANDERSEN GS, 1988, J HUM HYPERTENS, V2, P187
  • [3] BRAVO EL, 1988, HYPERTENSION, V11, P207
  • [4] FALSELY HIGH PLASMA POTASSIUM VALUES IN PATIENTS WITH HYPERALDOSTERONISM
    BROWN, JJ
    CHINN, RH
    DAVIES, DL
    FRASER, R
    LEVER, AF
    RAE, RJ
    ROBERTSON, JI
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1970, 2 (5700): : 18 - +
  • [5] Hyperaldosteronism among with resistant black and white subjects hypertension
    Calhoun, DA
    Nishizaka, MK
    Zaman, MA
    Thakkar, RB
    Weissmann, P
    [J]. HYPERTENSION, 2002, 40 (06) : 892 - 896
  • [6] Aldosteronism and hypertension
    Calhoun, David A.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (05): : 1039 - 1045
  • [7] Effect of spironolactone on blood pressure in subjects with resistant hypertension
    Chapman, Neil
    Dobson, Joanna
    Wilson, Sarah
    Dahlof, Bjorn
    Sever, Peter S.
    Wedel, Hans
    Poulter, Neil R.
    [J]. HYPERTENSION, 2007, 49 (04) : 839 - 845
  • [8] NORMOKALEMIC PRIMARY ALDOSTERONISM - A DETECTABLE CAUSE OF CURABLE ESSENTIAL HYPERTENSION
    CONN, JW
    COHEN, EL
    ROVNER, DR
    NESBIT, RM
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1965, 193 (03): : 200 - &
  • [9] Human adipocytes secrete mineralocorticoid-releasing factors
    Ehrhart-Bornstein, M
    Lamounier-Zepter, V
    Schraven, A
    Langenbach, J
    Willenberg, HS
    Barthel, A
    Hauner, H
    McCann, SM
    Scherbaum, WA
    Bornstein, SR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) : 14211 - 14216
  • [10] Low-renin status in therapy-resistent hypertension: a clue to efficient treatment
    Eide, IK
    Torjesen, PA
    Drolsum, A
    Babovic, A
    Lilledahl, NP
    [J]. JOURNAL OF HYPERTENSION, 2004, 22 (11) : 2217 - 2226